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LKB1/STK11 is a multitasking tumour suppressor kinase. Germline inactivating mutations of the gene are responsible for the Peutz-
Jeghers hereditary cancer syndrome. It is also somatically inactivated in approximately 30% of non-small-cell lung cancer (NSCLC).
Here, we report that LKB1/KRAS mutant NSCLC cell lines are sensitive to the MEK inhibitor CI-1040 shown by a dose-dependent
reduction in proliferation rate, whereas LKB1 and KRAS mutations alone do not confer similar sensitivity. We show that this subset of
NSCLC is also sensitised to the mTOR inhibitor rapamycin. Importantly, the data suggest that LKB1/KRAS mutant NSCLCs are a
genetically and functionally distinct subset and further suggest that this subset of lung cancers might afford an opportunity for
exploitation of anti-MAPK/mTOR-targeted therapies.
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LKB1/STK11 is a serine threonine kinase known to be involved in
several cellular processes including, signal transduction, energy
sensing and cell polarity (Spicer and Ashworth, 2004). Germline
inactivating mutations of LKB1 are known to cause Peutz-Jeghers
syndrome, a hereditary condition, which results in the develop-
ment of benign (hamartomatous) polyps in gastrointestinal tract,
mucocutaneous pigmentation (Hemminki et al, 1998; Mehenni
et al, 1998) and a predisposition to developing cancers in a variety
of tissues; colon, small intestine, breast, ovary, pancreas and lung
(Giardiello et al, 1987). Approximately 30% of somatic lung
adenocarcinomas harbour an inactivating mutation in LKB1
(Sanchez-Cespedes et al, 2002), and a recent study lists LKB1 as
one of the four most frequently mutated genes in lung
adenocarcinoma (Ding et al, 2008).
In mammalian cells, LKB1 exists in a complex with STE20-
related adaptor (STRAD) and mouse protein 25 (MO25; Boudeau
et al, 2003). It is a member of the calcium/calmodulin regulatory
kinase-like family and is thought to phosphorylate and activate at
least 13 kinases, including AMPK (Lizcano et al, 2004; Jaleel et al,
2005). AMP-activated protein kinase (AMPK) is a regulator of
cellular energy metabolism, and the main function of the pathway
is to restore cellular energy levels and is switched on in low ATP,
high AMP conditions, caused by processes, such as hypoxia and
cellular stress (Hardie et al, 2003). Activated AMPK phosphor-
ylates TSC2 activating the TSC1-2 complex, which inhibits RAS
homologue enriched in brain (RHEB), a small GTP-binding
protein and prevents the activation of mammalian target of
rapamycin (mTOR; Garami et al, 2003). The mammalian target of
rapamycin kinase plays a central role in regulating protein
synthesis and control of cell growth (cell size and mass) (Schmelzle
and Hall, 2000; Fingar et al, 2002). Loss of LKB1, therefore, leads to
a failure to inhibit RHEB and loss of suppression of mTOR
signalling, leading to increases in cell size and mass (Corradetti
et al, 2004; Shaw et al, 2004).
MATERIALS AND METHODS
Cell culture
Cell lines of a known genetic background (Table 1) were grown in
RPMI (Invitrogen, Life Technologies Inc., Carlsbad, CA, USA)
apart from CAL12T, which was grown in DMEM (Invitrogen)
supplemented with 10% FBS and 1% PSG.
Statistical analysis
Statistical analysis of the co-occurrence of LKB1 and ras-MAPK
pathway mutations in 87 NSCLC cell lines was carried out by the
Fisher’s exact test.
CI-1040/rapamycin treatment and proliferation assay
Cells were seeded in six replicates to 48-well plates. After 24h, this
was replaced with media containing 0, 0.1, 0.5, 1, 5, 10mM CI-1040
or 0, 0.1, 0.5, 1, 5, 10, 25, 50, 75, 100nM rapamycin (Sigma-Aldrich
Co, St Louis, MO, USA). After 72h, the proliferation rate was
measure using the CyQuant proliferation assay kit (Invitrogen)
according to the manufacturers instructions. Statistical analysis
was carried out using two-tailed unpaired t-tests.
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Cells were seeded to 6-well plates; 24h later, this was replaced with
media containing 0, 0.1, 0.5, 1, 5, 10mM CI-1040 or 0, 1, 10, 50, 100,
200nM rapamycin. Then 8 and 24h after the addition of CI-1040
and 24h after the addition of rapamycin, protein was harvested in
RIPA buffer containing protease (Sigma) and phosphatase (Roche
Applied Science, UK) inhibitors. Samples were mixed with pre-
Table 1 Mutation status of cell lines used in this study
LKB1 BRAF KRAS PIK3CA P53 CDNKA EGFR
Cell line Histology Mutation Mutation Mutation Mutation Mutation Mutation Mutation
SKMEL28 Malignant melanoma c.1799T4A
p.V600E
c.434_435TG4GT
p.L145R
c.2257C4T
p.P753S
CAL-12T NSCLC nos. No protein
a c.1397G4T
p.G466V
c.404G4T
p.C135F
c.172C4T
p.R58*
A549 NSCLC nos. c.109C4T
p.Q37*
c.34G4A
p.G12S
c.1_471del471
p.M1_*157del
NCI-H1734 NSCLC adenocarcinoma c.152_153insCT
p.M51fs*14
c.37G4T
p.G13C
NCI-H460 NSCLC large cell carcinoma c.109C4T
p.Q37*
c.183A4T
p.Q61H
c.1633G4A
p.E545K
c.1_457del457
p.?
NCI-H2030 NSCLC Adenocarcinoma c.949G4T
p.E317*
c.34G4T
p.G12C
c.785G4T
p.G262V
NCI-H1563 NSCLC adenocarcinoma c.816C4A
p.Y272*
c.1_471del471
p.M1_*157del
NCI-H2009 NSCLC adenocarcinoma c.35G4C
p.G12A
c.818G4T
p.R273L
NCI-H1975 NSCLC adenocarcinoma c.353G4A
p.G118D
c.818G4A
p.R273H
c.205G4T
p.E69*
c.2573T4G
p.L858R
NCI-H1838 NSCLC adenocarcinoma c.818G4T
p.R273L
c.1_471del471
p.M1_*157del
Mutation status of oncogenes and tumour suppressors known to be commonly mutated in NSCLC. Mutation data taken from COSMIC (http://www.sanger.ac.uk/genetics/CGP/
CellLines/).
aNo mutation has been found in this sample by sequencing; however, immunoblot analysis revealed no protein present (data not shown); NSCLC nos.¼NSCLC not
otherwise specified.
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Figure 1 Statistical and biological significance of LKB1 mutations and RAS-MAPK pathway mutations. (A) Statistical analysis of 87 lung cancer cell lines by
the Fisher’s exact test. (B) Venn diagram showing the overlap of LKB1, KRAS and BRAF mutations. (C) Snapshot of cross-talk between LKB1 and RAS-
MAPK signalling pathways compiled by the analysis of literature (for references, see main text).
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smade sample buffer and reducing agent (NUPAGE) and trans-
ferred to a PVDF membrane (Invitrogen) by western blotting.
Membranes were probed with rabbit anti-ERK, anti-phospho ERK
(Cell Signalling, 1/1000), anti-cyclin D1 (Santa Cruz, 1/500),
p70S6K and phosphop70S6K (thr389) (Cell Signalling, 1/1000),
followed by secondary antibodies (Cell Signalling, 1/2500).
The bands were displayed using enhanced chemiluminescence
method (Pierce Biotechnology Inc., Rockford, IL, USA).
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Figure 2 Cells with inactivated LKB1 and activated KRAS are more sensitive to the MEK inhibitor CI-1040 and the mTOR inhibitor rapamycin; however,
dual inhibition is neither additive nor synergistic. Cell lines tested: NCI-H460 (LKB1
-/-/KRASmut), A549 (LKB1
 / /KRASmut), NCI-H1734 (LKB1
 / /KRASmut),
NCI-H2030 (LKB1
 / /KRASmut), collectively labelled as LKB1
 / /KRASmut in the figure; NCI-H1838 (wt), NCI-H1975 (wt), NCI-H2009 (KRASmut), NCI-
H1563 (LKB1
 / ), collectively labelled as control cell lines; CAL12T (LKB1
 / /BRAFmut), and SKMEL28 (positive control, BRAF V600)( A) Cells were seeded
in six replicates to 48-well plates. After 24h, this was replaced with a medium containing 0, 0.1, 0.5, 1, 5 or 10mM CI-1040. After 72h, proliferation rate was
determined using CyQuant proliferation assay (Invitrogen) according to the manufacturer’s instructions. The results shown here are from two independent
experiments. Proliferation rates were measured relative to the untreated control. (B) Values from the two clusters shown in panel A were averaged to
calculate the statistical significance between the clusters, values shown ±s.d between the cell lines within the cluster, nX4 for each cluster. Two-tailed
unpaired t-test gave a P-value of o0.001 for all CI-1040 concentrations. (C) The same protocol as in panel A was followed; however, after 24h, this was
replaced with a medium containing 0, 0.1, 0.5, 1, 10, 25, 50, 75 and 100nM rapamycin. The results shown here are again from two independent experiments.
Proliferation rates were measured relative to the untreated control. Owing to the similar nature of the results of the CI-1040 experiment, the cell lines were
clustered according to their mutation status (LKB1
 / /KRASmut) or control cells (LKB1
 / , WT and KRAS mut). Unpaired two-tailed t-tests carried out to
determine statistical significance; Po0.05 for concentrations of 10nM and upwards, n¼3 for each cluster means ±s.d. (D) Dual inhibition experiments were
carried out using 10nM rapamycin and a range of CI-1040 concentrations in the same format as single-agent experiments, cell lines were again grouped by
their mutation status and statistical significance calculated using two-tailed unpaired t-tests, Pp0.01; results are from two independent experiments each with
six replicates, mean±s.d. (E) Comparison of dual-agent treatment to most potent single-agent treatment to determine whether the agents are additive/
synergistic in the LKB1
 / /KRASmut group. Statistical significance determined using unpaired two-tailed t-tests between single-agent treatment group and
each dual-treatment group. The only significant value marked *P¼0.005, n¼3, mean±s.d. (F) Comparison of dual-agent treatment to most potent single-
agent treatment in control cell lines to determine whether the agents are additive/synergistic in the control group. No statistically significant values were
found, n¼3, means±s.d.
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Resequencing of known cancer genes in a series of 87 NSCLC cell
lines (http://www.sanger.ac.uk/genetics/CGP/CellLines/) found
significant association of LKB1 inactivating mutations with KRAS
mutations (P¼0.03). This association has recently been confirmed
in an independent study (Matsumoto et al, 2007). Association of
LKB1 inactivation clustering with non-V600 BRAF mutations
(Figures 1A and B) was also observed. LKB1 and RAS/RAF/MEK
(MAPK) signalling pathways are linked through RHEB, which
when active, activates mTOR and inhibits wild-type BRAF, but not
the mutated form (Im et al, 2002; Garami et al, 2003; Karbow-
niczek et al, 2004). It was recently shown that the inhibition of
RAF1 (cRAF) activity by RHEB prevents heterodimerisation of
BRAF and RAF1 (Karbowniczek et al, 2006). LKB1 mutations in
NSCLC may, therefore, have a general requirement for an
activation of the MAPK cascade to overcome suppression through
RHEB inhibition. This interdependence suggests that the inhibi-
tion of MAPK signalling may constitute a potential opportunity for
therapeutic intervention in this genetic subset of NSCLC
(Figure 1C).
To further explore this potential, NSCLC lines of known genetic
backgrounds (Table 1) were treated with the MEK inhibitor
CI-1040. Figure 2A shows that the LKB1/KRAS mutant cell lines
have a uniform enhanced sensitivity to CI-1040 when compared
with wild-type cell lines, LKB1 mutant lines or KRAS mutant lines
(labelled control cell lines in Figure 2B). Interestingly, the LKB1/
BRAFG466V mutant cell line (CAL12T) is insensitive to CI-1040
and falls in the top cluster. The mean relative proliferation rate
calculated for LKB1/KRAS mutant cell lines, and compared with
the control cell line cluster was statistically significant (Po0.001 at
all CI-1040 concentrations 40; Figure 2B). LKB1/KRAS mutant cell
lines have a mean IC50 value of 5mM compared with the control cell
lines, which have a mean IC50410mM. We next investigated the
importance of mTOR signalling in the genetic subtypes of lung
cancers under study. Figure 2C shows that inhibiting mTOR using
rapamycin had a more pronounced affect on proliferation in LKB1/
KRAS mutant cell lines; in this case, the sensitive cluster also
included the LKB1/BRAF mutant cell line CAL12T. The IC50 of the
LKB1/MAPK mutant cluster was significantly different from the
control cluster (40nM vs 4100nM, Pp0.04). Dual inhibition of
MEK and mTOR (Figure 2D) leads to a statistically significant
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24hrs
A549
NCI-H1838
NCI-H2009
NCI-H460
NCI-H1734
NCI-H1563
ERK
CI-1040 (M) 0 0.1 0.5 1 5 10
0 0.1 0.5 1 5 10
0 0.1 0.5 1 5 10 0 0.1 0.5 1 5 10
0 0.1 0.5 1 5 10
0 0.1 0.5 1 5 10 0 0.1 0.5 1 5 10
0 0.1 0.5 1 5 10
LKB1–/–/KRASmut 
WT
KRASmut
LKB1–/–
NCI-H460
NCI-H2009
NCI-H1734
NCI-H1838 
A549
NCI-H1563
CI-1040 (M)
LKB1–/–/KRASmut 
LKB1–/–/KRASmut 
LKB1–/–/KRASmut 
WT
KRASmut
LKB1–/–
LKB1–/–/KRASmut 
LKB1–/–/KRASmut 
LKB1–/–/KRASmut 
WT
KRASmut
LKB1–/–
LKB1–/–/KRASmut 
LKB1–/–/KRASmut 
WT
KRASmut
LKB1–/–
LKB1–/–/KRASmut 
p70S6K
NCI-H1838
NCI-H1563
A549
CI-1040 (M)
NCI-H460
NCI-H2009
phospho-p70S6K (thr389)
24hrs
Rapamycin(nM) 0 1 10 50100 200 0 1 10 50 100 200
CyclinD1
NCI-H2009
A549
NCI-H460
NCI-H1838
NCI-H1563
phospho-p70S6K (thr389)
24hrs
phosphoERK Cyclin D1
Figure 3 The sensitivity to the MEK inhibitor CI-1040 and the mTOR inhibitor rapamycin are not due to downstream effects on cyclin D1, but in the case
of MEK inhibition are due to downstream effects on phospho-P70S6K (thr389). (A) To determine the effect of MEK inhibition on MAPK downstream
pathway components cells were seeded to 6- well plates, and the following day, it was replaced with media containing 0, 0.1, 0.5, 1, 5, 10mM CI-1040. After 8
and 24h, the addition of CI-1040 protein was harvested in RIPA buffer containing protease (Sigma) and phosphatase (Roche) inhibitors. Samples were
mixed with premade sample buffer and reducing agent (NUPAGE), and heated at 951C for 5mins. In all, 10ug of protein was run on a 4–12% precast gel
(NUPAGE), and transferred to a PVDF membrane (Invitrogen) by western blotting. Membranes were probed with either rabbit anti-ERK, antiphospho ERK
(Cell Signalling, 1/1000), anticyclin D1 (santa-cruz, 1/500) antibodies, followed by secondary antibodies (Cell Signalling, 1/2500). The bands on the
membrane were displayed using enhanced chemiluminescence method (Pierce). (B and C) Using the same immunoblotting protocol as above, mTOR
downstream pathway components were assessed after treatment with CI-1040 or rapamycin. Total p70S6K and phospho-p70S6K (thr389; Cell signalling,
1/1000) protein levels were analysed in 0, 0.1, 0.5, 1, 5, 10mM CI-1040- treated cell lines. Phospho-p70S6K (thr389) and cyclin D1 protein levels were
analysed in cell lines treated with 0, 1, 10, 50, 100 and 200nM rapamycin.
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versus the control cell lines (P-value: p0.01). This effect of dual
inhibition in general did not reach statistical significance for
additivity nor being synergistic in either cluster (Figures 2E and F),
although at the highest concentrations (5mM CI-1040 with 10nM
rapamycin) in the LKB1/KRAS mutant cluster, the data were
consistent with an additive model. However, this may be due to the
combined toxic effects of higher drug concentrations.
To confirm that MEK inhibition was being achieved in the cells,
we carried out immunoblot analysis of ERK, phosphorylated ERK
and cyclin D1 levels at 8 and 24h following CI-1040 treatment
(Figure 3A). In all cell lines, levels of phosphorylated ERK
decreased with increasing CI-1040 concentration by 8h; however,
wild-type cell lines for both genes or LKB1 mutant required higher
concentrations of CI-1040 to prevent phosphorylation of ERK. The
effect of MEK inhibition on cyclin D1 levels did not appear to
correlate with genetic status, and interestingly, the KRAS mutant
cell line NCI-H2009 showed a similar decrease in phosphorylated
ERK, and perhaps the greatest decrease in cyclin D1 levels, despite
the inhibitor having little effect on proliferation. Altogether, these
data show that the effects of MEK inhibition on phospho-ERK are
driven by the presence or absence of a KRAS mutation and are
independent of LKB1 mutation status, whereas the proliferation
effects are related to LKB1/KRAS combined mutation status. As
there was no correlation with cyclin D1 levels and enhanced
sensitivity to MEK inhibition, we carried out immunoblot analysis
of p70S6K and phospho-p70S6K (thr-389) levels; phosphorylation
of this residue is critical for kinase function (Pullen and Thomas,
1997). Figure 3B shows that CI-1040 treatment had no effect on
total p70S6K protein levels; however, a decrease was observed in
phospho-p70S6K (thr-389) levels, specifically in LKB1/KRAS
mutant cell lines. This decrease in phosphorylation correlated
well with the observed IC50 for this genetic subset. Figure 3c shows
that rapamycin treatment had no effect on cyclin D1 protein levels,
but had a potent effect on phospho-p70S6K (thr-389) levels in all
cell lines regardless of the mutation status.
DISCUSSION
Here, we report that LKB1 inactivation and KRAS activation in
non-small-cell lung cancer denotes a functionally distinct set of
lung cancer, which display sensitivity to the single-agent treatment
with the MEK inhibitor CI-1040 or rapamycin. It has been
previously shown in melanomas that treatment with CI-1040
caused a dose-dependent reduction in phospho-ERK and cyclin D1
protein levels in BRAFV600E mutant cell lines, but not in NRAS
mutant melanomas (Solit et al, 2006). Our results, while showing
dose-dependent reduction of phospho-ERK in KRAS mutant
NSCLC cell lines, show inhibition of proliferation only in the
subset with both KRAS and LKB1 mutations, highlighting
the importance of the cross-talk in these pathways and supporting
the genetic data that the co-occurrence of these two mutations is
non-random. Dose-dependent decrease in phospho-ERK and
reduction in proliferation rate did not result in a corresponding
decrease in cyclin D1 levels, suggesting that in this subset of
NSCLC, the downstream effecter pathways may be different to
BRAFV600E melanomas. The effects of reduced proliferation in
this genetic subset may be due to the reduction in the activity of
p70S6K, which is downstream of both mTOR and ERK1/2, shown
by the specific reduction of phosphorylation of thr-389 P70S6K in
LKB1/KRAS cell lines following MEK inhibition. These data further
highlight the importance of cross-talk between these pathways in
this genetic subset. Interestingly, CAL12T, the LKB1/BRAF mutant
cell line is insensitive to CI-1040 yet sensitive rapamycin,
suggesting an additional, smaller genetic subset in NSCLC and
possibly highlighting the difference of the non-V600 BRAF
mutations found in NSCLC (Brose et al, 2002). Despite being
sensitised to CI-1040 and rapamycin, dual-agent treatment did not
have demonstrably additive or synergistic effects in LKB1/KRAS
cell lines, suggesting the possible redundancy in the pathways. The
lack of additivity may be explained by the observation that
rapamycin potently inhibits p70S6K phosphorylation at thr-389,
therefore precluding any additional effect of CI-1040 on the
p70S6K activity, further confirming redundancy of the pathways in
this genetic subset of NSCLC.
Mutation status in cancers has been shown to predict response
to targeted therapies, as exemplified by the efficacy of EGFR
inhibitors in EGFR mutant lung cancer (Lynch et al, 2004; Paez
et al, 2004). Data presented here suggest that LKB1/KRAS mutated
tumours are a genetic and functionally distinct subset of NSCLC.
Further, these data suggest that investigation of this subset of lung
cancers with respect to newer generation inhibitors of MAPK and
mTOR signalling pathways may provide a new opportunity for
investigation of targeted therapeutics in this common adult
malignancy.
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